TY - JOUR
T1 - Molecular biomarkers for the evaluation of colorectal cancer
T2 - Guideline from the American society for clinical pathology, college of American pathologists, association for molecular pathology, and American society of clinical oncology
AU - Sepulveda, Antonia R.
AU - Hamilton, Stanley R.
AU - Allegra, Carmen J.
AU - Grody, Wayne
AU - Cushman-Vokoun, Allison M.
AU - Funkhouser, William K.
AU - Kopetz, Scott E.
AU - Lieu, Christopher
AU - Lindor, Noralane M.
AU - Minsky, Bruce D.
AU - Monzon, Federico A.
AU - Sargent, Daniel J.
AU - Singh, Veena M.
AU - Willis, Joseph
AU - Clark, Jennifer
AU - Colasacco, Carol
AU - Bryan Rumble, R.
AU - Temple-Smolkin, Robyn
AU - Ventura, Christina B.
AU - Nowak, Jan A.
PY - 2017/5
Y1 - 2017/5
N2 - Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.
AB - Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.
UR - http://www.scopus.com/inward/record.url?scp=85012091267&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85012091267&partnerID=8YFLogxK
U2 - 10.5858/arpa.2016-0554-CP
DO - 10.5858/arpa.2016-0554-CP
M3 - Article
C2 - 28165284
AN - SCOPUS:85012091267
SN - 0003-9985
VL - 141
SP - 625
EP - 657
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
IS - 5
ER -